Genmab A/S ADS (GMAB) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, GMAB carries an RQD Score of 70 and a letter grade of B-, labeled "Roarable Buy — Sound Institutional Accumulation." The five pillars are: Fundamental Cash Engine 11/20 (ROIC 9.9%; FCF yield 2.21%); Whale 13F Flow 18/20 (institutional accumulation and options positioning); Insider Conviction 12/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 13/20 (Beta 1.09; sector sensitivity); and Forensic Balance Sheet 16/20 (Altman Z 3.74; Piotroski F 8/9; Debt/Equity 0.39). For a prospective investor, the strongest pillar is institutional flow and the weakest is the cash-generation pillar, where a 2.21% FCF yield sits against a trailing P/E of 32.8, implying the valuation leans on future earnings growth rather than current cash returns. The balance sheet pillar is the most supportive of downside resilience. Insider conviction and macro fit are mid-range, so the rating reflects a constructive but not decisively strong profile.

Per the recent news feed, four headlines are tagged to GMAB, all carrying a YELLOW light and a MARKET WIRE impact label. They describe short-term price action: a 0.81% gain with shares reported holding above $37, a 1.64% slip as shares tested a support zone, a 2.46% decline to $55.88 near the lower end of a recent range, and a 1.48% gain to $39.07 described as put-dominated. The headlines are price-movement commentary rather than company-specific fundamental events, and several cite price levels (around $37 and $39) that are inconsistent with the $56.49 price in the market data, so they should be treated with caution. Risk watch items per the feed are the reported support test and range-low breach. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded (supply chain: NONE).

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations, but no upstream or downstream dependencies, sector correlations, or second-order bottlenecks are documented in the source data. Investors should note that this absence is a gap in the data rather than evidence of no ripple exposure.

• What are the company's reported revenue, operating income, net income, and cash-flow figures by period? (Financials section is absent.)
• What is the analyst consensus rating and price-target distribution? (Analyst data is absent.)
• Which institutions hold GMAB, and what are the 13F and Form 4 insider transactions behind the whale and insider pillar scores? (Holders data is absent.)
• Why do the news headlines cite price levels of roughly $37 and $39 when the market data shows $56.49?
• What does the company sell and to whom, and what pipeline or product catalysts drive its growth? (Business profile detail is absent.)